heart infarction Ischemia-reperfusion injury
Conditions
Interventions
24 healthy male volunteers receive a one week treatment with 20 mg rosuvastatin
daily. On day 7, after at least 24 hours of caffeine abstinence all volunteers
will be randomised to receive either pl
Sponsors
Universitair Medisch Centrum Sint Radboud
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: Male age between 18-50 yrs signed informed consent
Exclusion criteria
Exclusion criteria: -Cardiovascular disease -Hypertension (systole > 140 mmHg, diastole > 90 mmHg) -Hypercholesterolemia (fasting total cholesterol > 6,0 mmol/l) -Drug abuse -Concomittant medication use -Inability to perform the ischemic isometric muscle contraction -Diabetes Mellitus (fasting glucose > 7.0 mmol/L or random glucose > 11.0 mmol/L) -Alanine-Amino-Transferase (ALAT) >90U/L (more than twice the upper level of the normal range) -Creatinine Kinase (CK) >340U/L (more than twice the upper level of the normal range) -Participation in any trial concerning medicinal products during the last 60 days prior to this study. -Participation in clinical trial involving administration of radioactivity more than 5mSv, during the 5 years prior to this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Annexin A5 targeting (% difference in radioactivity (counts per pixel) between experimental and control thenar muscle after ischemic exercise, as a indicator for ischemia reperfusion injury. | — |
Secondary
| Measure | Time frame |
|---|---|
| -Workload (product of 50% of the maximum forearm force and duration of the ischemic exercise) -The effect of one-week treatment of rosuvastatine 20mg once daily on lipid spectrum. -The caffeine serum concentration after 24 hour abstinence, and after infusion of cafeine (4mg/kg) or placebo. | — |
Countries
Netherlands
Outcome results
None listed